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pfl!.ctice of medicine by the general practitioner. In spite of
thi~, however, it remains true to say that we have not com-
pletely outgrown the usefulness of the time-honoured art of
c1iJlical medicine.
jn order to try to give some guidance in the numerous
prclblems of management and treatment with which the
modem general practitioner is confronted, and in order to
arrive at a re-evaluation and a synthesi between proved
clinical methods of treatment and the newer scientific
approaches, we have invited distinguised contributors to
provide a series of signed articles which it is hoped will be
helpful to the practitioner. These articles will be published
at fortnightly intervals.
Met die doel om te probeer om leidmg te gee ten opsigte
van die baie probleme aangaande die hantering van pasiente
en behandeling waarmee die algemene praktisyn te doen kry,
en in die hoop om tot 'n herwaardering en 'n sintese te
geraak tussen kliniese metodes van behandeling en die
nuwere wetenskaplike benaderings, het ons 'n aantal bekende
medewerkers gevra om 'n reeks getekende artikels te skryf
wat, na ons hoop, van nut sal wees vir die algemene praktisyn.
Hierdie artikels sal at om die ander week gepubliseer word.
,ALGEMENE PRAKTISYNSREEKS'
Dit teorie en die pralctyk van die modeme medisyne het met
sulke rasse skrede vooruitgegaan dat dit geen oordrywing
sal wees nie om te se dat die hele medisyne wesenlik verander
het. ~ierdie verandering is veral merkbaar op die gebiede
varl dIe narkose, operasietegnieke en die behandeling van
sieI<.tes met medisyne, maar dit het ook 'n baie belangrike
neerslag gehad op die mediese praktyk soos beoefen deur
die algemene pralctisyn. Ten spyte hiervan bly dit egter tog
nog waar om te se dat ons nog nie die waarde van die ou
beproefde kuns van die kliniese medisyne ontgroei het nie.
SOME CLINICAL ASPECTS OF DIABETES WITH RELATION TO I SULIN
AND TOLBUTAMIDE
A DISCURSIVE SURVEY WHICH ASKS SOME QUESTIO S BUT A SWERS ONE-
W. P. U. JACKSON, M.A., M.D., M.R.C.P., D.C.H.,
Diabetic Clinic, Department of Medicine, Groote Schuur Hospital and University of Cape Town
• A. VARIETIES OF DIABETES
I should like to start by reaffinning the clinical separation
of diabetes mellitus into 3 types, severe, nlild, and secondary.
'Severe' refers to the usually young, growth-onset, ketosis-
prone individual, who needs insulin to live. 'Mild' refers to
the usually older, maturity-onset, often obese person, who
does not become ketotic when insulin is onlitted, although
he (or more usually she) may be relatively insensitive to
insulin and require 100 or even more units to produce any
obvious effect on her carbohydrate metabolism. The dose
of insulin being used is no criterion of the severity of the
diabetes. Severe and nlild diabetes are sometimes called
'~ancreatic' and 'extrapancreatic' respectively, on the assump-
tIOn that the disease in the first case is due to destruction of
pancreatic beta-eells, and in the second to anti-insulin
factors which mayor may not be hormonal. However,
insulin antagonists have been found in the blood-stream of
the severe diabetic rather than in the mild case, while islet-eell
damage probably always occurs in the pancreas of the mild
diabetic, in whom both Ogilvie1 and Gepts2 have found an
invariable reduction in amount of islet tissue. Vallance-
Owen3 has shown that the insulin-like activity in the blood-
stream of the mild diabetic is of the same order as in a fasting
normal person. This, however, does not mean that the
pancreatic activity is normal; far from it, since an induced
rise of blood sugar in the normal to the height of that in
the mild diabetic produces a several-fold increase in plasma-
• Being a contribution to a symposium on 'The mechanism
of a.ction of insulin and other hypoglycaemic substances', London,
IO September 1958, under the auspices of the Briti.sh Insulin
Manufacturers.
insulin activity. Thus the mild diabetic possesses a pancreas
which is unable to respond normally to the stimulus of a
raised glucose level.
It may be noted that the terms 'mild' and 'severe' refer
only to the evidence of abnormality of metabolism; both
types may develop the same cripplmg or killing vascular
complications, both may present similar inheritance patterns
and occur together in the same family, and both may give
evidence of their latent existence by the same sort of abnormal
obstetric history and embryopathy in the prediabetic phase. It
is also true that a mild diabetic may develop ketosis under
the influence of certain forms of stress, while occasionally
a severe diabetic reverts to the mild form. I have twice seen
patients in hospital in diabetic coma, without any known
precipitating factors, who were normoglycaemic some months
later without insulin. Nevertheless the clinical differentiation
of the main primary types of diabetes is extremely important
and remarkably often neglected. For instance, figures con-
cerning the clinical use of sulphonylureas with regard to age
of patient, insulin dosage and so on are quite useless unless
the two diabetic groups have first been clearly separated.
'Secondary' diabetes refers most obviously to that which
follows chronic destructive pancreatitis, haemochromatosis
or total pancreatectomy. The diabetes which occurs during
pregnancy, staphylococcaI infections or acromegaly, or with
moderate doses of glucocorticoids, is not truly secondary,
but rather the unmasking of an und.erlying latent or pre-
diabetic state. Fig. I shows a corticoid diabetic (European
male aged 35, suffering from gout) becoming apparently
normal after cessation of treatment, but again diabetic-this
time permanently-a few months later.
/
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Fig. J. 'True' diabetes uncovered by cortisone. I. Diabetic
after 4 months on cOrlisone. 2. 'ormal curve off cortisone.
3. Eight months later, no more cortisone: again diabetic.
(Glucose-lOlerance curves using 50 g. of glucose by mouth.)
PREDIABETES AND VASCULAR DISEASE
Many of us believe that, strictly speaking, diabetes begins
at birth, that the basic abnormality, whatever it may be, is
present for the whole of the lifetime of the diabetic, although
the overt carbohydrate defect may not be manifest until
middle age. Time precludes discussion of the arguments in
favour of this belief, beyond my remarking that the elderly
diabetic who attends your clinic may give a history of large
babies and stillbirths which extends back 30, 40 or 50 years
into her prediabetic past. Furthermore we consider that the
specific vascular abnormalities of diabetes are not 'com-
plications' but are an integral part of the syndrome, inherited
together with the metabolic disturbances. Usually they appear
later than the hyperglycaemia, but sometimes before it.
They are not a con equence of hyperglycaemia, and normali-
zation of the latter, even in the very mildest cases, is no
safeguard against their occurrence. It would, however,
appear that they are closely connected with pancreatic
damage, since true secondary pancreatic diabetes has
occa ionaUy led to the later development of specific retino-
pathy or nephropathy.
The e various observations are extremely important, since
they appear to intimate that a defect of pancreatic islet tissue
may produce a diabetic vasculopathy which is not dependent
upon hyperglycaemia. Indeed we have perhaps been over-
ob es ed with hyperglycaemia as the primary feature of
diabetes. Insulin has an action in fat metabolism which may
well be more important than its more obvious effect on
INSULIN A 'D PREDIABETES
carbohydrate. It is closely related to the level of the non-
esterified fatly acids, and stimulates rapid metabolism in
fatty tissue. It has now been shown to exert an influence on
amino-acid metabolism.' Might it perhaps have an essential
protective effect on blood-vessel walls? A future diabetic
might be born with a relatively inefficient beta-cell mechanism,
not so defective tbat our rough yardsticks of definition based
on glucose IOlerance can detect it, but bad enough that
throughout the years certain blood vessels in certain places
become progressively damaged. The special stress of preg-
nancy may indicate the latent deficiency by producing
temporary carbohydrate intolerance in the mother, death or
excessive size of the foetus, and hyperplasia of the foetal
islets of Langerhans.
This hyperplasia of the islets of Langerhans in the foetus of a
diabetic or a prediabetic mother is a remarkable phenomenon.
Table I shows the relative proportions of islet tissue to the
TABLE l. PROPORTIONS OF ISLET TISSUE I PANCREASES IN DIFFERENT
GROUPS (EXPRESSED AS MEA PERCE TAGES OF TOTAL PANCREAS)
Control stillbirths. . 1· 3~~
Stillbirths of diabetic mothers 6· 5 %
Stillbirths of prediabetic mothers 7· 5%
Stillborn with erythroblastosis foetaIis .. 7· J %
whole pancreas which Woolf and I' found on examination
of 108 pancreases from stillborn 'infants. Fig. 2 illustrates a
pancreas from the foetus of a prediabetic mother (B) com-
pared to a normal at the same magnification (A). From
the small amount of suitable material available to us, it
seems that not only are the islets large and increased in
number, but they contain an unusually high proportion of
beta cells, and these beta cells contain an unusually great
concentration of granules. If granules really represent
insulin, then it would appear that the pancreas of such a •
foetus may contain up to 30 times as much insulin as normal.
What could be the cause of this beta-cell hyperplasia? It
is not hyperglycaemia, because it occurs in the absence of
hyperglycaemia in the prediabetic. Growth hormone and
glucocorticoids have been much discussed in connection
with the diabetic embryopathy, but there are cogent arguments
against either of these as the sole or primary villain of the
piece. Might not the maternal lack of pancreatic reserve
during pregnancy militate through some mechanism other
than hyperglycaemia to allow a compensatory hypertrophy
of the infant's islets? ow the excessive insulin produced
by the infant might itself act as a 'growth hormone' in its
own intra-uterine development. Could this possibly account
for the excessive size of the diabetic's baby?
If this story has any truth, then insulin might be expected
to prevent the diabetic vascular abnormalities, the foetal
and obstetric abnormalities, and possibly the actual develop-
ment of overt diabetes in a prediabetic. Certainly, and
unfortunately, insulin will not prevent all vascular disease in
diabetics, but there is much evidence that when it is given in
such a way that good control of glucose metabolism is
achieved then the liability to vascular lesions is, in general,
considerably lessened. Figures from our own clinic indicate
that the incidence of retinopathy and neuropathy in poorly
controlled diabetics was double that in diabetics who e
control was good or excellent. ow if our belief regarding
1·5
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Fig. 2A: PhotomicrQgraph of pancreas of stillborn of normal mother. Fig. 28. Photomicrograph of pancreas of stillborn
of prediabetic mother.
fig. 3. The blacked-in figures represent diabetics. The pro-
band (arrowed) had a diabetic son, mother, and grandmother.
There was no diabetes on his wife's side. He did not know
he was diabetic, but the family history led to hi having a
glucose tolerance test; result as given.
the presence of diabetes from birth is true, it is surely plain
that insulin given only when overt carbohydrate defects
are present would not be expected to prevent a lesion which
has already been developing for a long time. U we could give
insulin early in the prediabetic phase, might we not then
prevent the vascular di ease? Thi, of cour e, i not known,
but it is worth considering. Methods used in diagnosing
prediabetes] will not consider here, but it may be mentioned
that certain family histories make a diagno i of pre- or
latent diabetes mandatory; for instance when both parents
are diabetic, when an identical twin is diabetic, or in uch a
family as is shown in Fig. 3. Prof. Hoet6 has indeed some
evidence that insulin given to a prediabetic woman during
pregnancy will prevent the development of severe congenital
abnormalities, while Wilkerson 7 from Boston ha shown that
the same treatment will tend to reduce the birth weight of
the foetus. Further, Hoet' has pointed out that the child
of a known diabetic mother being treated with insulin
seldom becomes diabetic under the age of 10, whereas
almost all mothers of children who become diabetic under
the age of 6 are untreated latent or pre-diabetics. Insulin
given during pregnancy may thus have a protective action
on the child. ]s it just possible that insulin given to children
in diabetic families would prevent diabete entirely? It
protects the pancrea of animals against alloxan.
]t is admittedly impracticable to uggest that babies or even
adult should be stuck with a needle every day without a
great deal more evidence of its value. ould the oral ul-
phonylurea take the place of insulin in prophylaxi ? It is very
important that we hould know the mode of action of these
substance before embarking on uch a programme. Jf their
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major action is a stimulation of beta cells with the production
of insulin, then there are two ways in which their use in
prophylaxis would differ from that of insulin. First it might
be presumed to overtax the already inefficient beta cells,
rather than to rest them. The whole idea of continued
stimulation produciqg permanent structural damage to the
beta cells is, however, rather nebulous, has been too readily
accepted, and finds no proven counterpart in the rest of the
endocrine system, nor indeed in other organs of the body.
Gepts," furthermore, has found that the damage to islet cells
in elderly patients treated with carbutamide or tolbutamide
is no greater than that seen in a group of similar untreated
or insulin-treated diabetics, while in some he found actual
regeneration of apparently active beta cells. The second
difference between tolbutamide and exogenous insulin is
that the endogenous insulin which is formed under the in-
fluence of tolbutamide would be liberated into the portal
system, and so might really act more physiologically than
insulin injected peripherally. Thus Madison and UngerS
have shown that insulin administered intraportally in dogs
produces a much smaller arteria-venous glucose difference
than when systematically introduced, suggesting a lesser effect
on muscle and probably a greater hepatic effect. Tolbutamide
does not appear to be toxic in other ways-in fact it seems
to be about the most non-toxic drug ever produced. Theo-
retically it might appear inadvisable to give it to a prediabetic
or diabetic during pregnancy, since we have evidence that
the beta cells of the foetus are already being excessively
stimulated. Although tolbutamide might be called simply a
drug of convenience in the treatment of the established mild
diabetic, it may yet be of true value if used early enough,
especially in the prediabetic.
The advent of the antidiabetic sulphonamides has taught
us more about diabetes as seen in the clinic. In the trial of
carbutamide and tolbutamide which we carried out, we made
it a rule to withhold all insulin from our mild diabetics for
several weeks before starting the new drug, in order to
obtain a proper control base-line. We were surprised to
find the number of patients whose carbohydrate metabolism
was as well controlled on diet only as it had been with insulin
also. In fact in a few the control was actually better without
·insulin. This has led to a considerable reduction in the
number of patients taking insulin in our clinic. Furthermore
it clearly indicates that any trial of an oral preparation in
diabetes is valueless without periods during which no drug
at all is taken. Although insulin was apparently being given
unnecessarily to the above-mentioned patients, yet perusal
of their previous records frequently indicated that it had
been prescribed to good purpose when originally adminis-
tered, 2, 3, or 5 years before. This might be interpreted in 2
ways; either the disease in its natural course had become
milder or, as I prefer to think, the insulin had really had a
partially curative effect.
Some clinics in Britain have been strongly advocating a
return to the use of soluble insulin alone for the control of
all severe, insulin-dependent diabetics. They claim not only
better carbohydrate control, but also a greater protection
against vascular disease than is afforded by long-acting
insulins. I do not consider they have proved either point,
and it must be remembered that the long-acting insulins were
introduced largely because 2 injections of soluble a day were
inefficient in diabetic control. We have found, after seme 5
years experience, that the lente group of insulins are generally
satisfactory and we consider that their wholesale abandon-
ment would be a retrograde step unless further evidence is
forthcoming to warrant such a procedure.
PRIME IMPORTANCE OF VASCULAR DISEASE
Despite the above arguments I do not wish to overemphasize
the potential protective value of insulin in diabetes. Now that
coma is a relatively minor problem, the importance of diabetes
does not lie in its carbohydrate control but in its vasculo-
pathies-retinopathy, neuropathy (assuming that this is
basically vascular), nephropathy, and coronary and peripheral
vascular disease. The blood sugar of itself is a matter of
little importance. Although good control of diabetes as
measured by glucose estimations may partially prevent the
specific diabetic vasculopathies, yet it has little or no effect
on the development of coronary heart disease.s We have
observed this in figures from our own clinic. Normally,
pre-menopausal women are considerably protected from the
clinical manifestations of coronary atheroma by the very
fact of their womanhood. In this respect diabetes abolishes the
advantage of being born a woman. If, however, the coronary
arteries can really be protected by a low intake of saturated fat,
then surely the very first place in which this type of diet should
be advised is tbe diabetic clinic? If the carbohydrate intake is
increased and socalled 'control' rendered more difficult, is
there any evidence at all that this would matter? It seems to
me that many 'diabetic diets' being used today are probably
atherogenic. As recently as June 1958 a report of the Council
on Food and Nutrition (US) recommended that 40 % of
calories in a diabetic's diet should come from fat. Admittedly
a small face-saving, and rather ingenuous, rider was added:
'with unbydrogenated vegetable oils substituted to a con-
siderable extent for hard cooking fats'. Comment on the
utter inadequacy of sucb advice should be unnecessary.
There is certainly less evidence that the specific diabetic
vascular lesions might be reduced by a lowered fat intake,
but this is something that must be investigated.
CONCLUSION
'1 think that all this may be summarized by the suggestion
that insulin, and even possibly the oral sulphonylureas, may
have a greater potentially protective action in diabetes than
we realize, but that drugs alone are not likely to solve the
real clinical problem of diabetes-the vascular one. We
still do not know how best to treat diabetes and are only
just beginning to think about preventing it.
I should like to take this opportunity of thanking the British
Insulin Manufacturers and especially Dr. F. Wolff for arranging
the symposium; also Prof. J. F. Brock and Dr. J. H. Sheldon
for reading this manuscript. Drs. N. Woolf and J. A. H. Campbell
are responsible for the photomicrographs of the islets (Fig. 2).
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